Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Pharma & Biotech
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.